Jounce Therapeutics, Inc. announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced operating income was USD 35.421 million compared to operating loss of USD 23.532 million a year ago. Net income was USD 35.472 million compared to net loss of USD 22.667 million a year ago. Basic earnings per share from continuing operations was USD 0.9 compared to basic loss per share from continuing operations of USD 0.68 a year ago. Diluted earnings per share from continuing operations was USD 0.86 compared to diluted loss per share from continuing operations of USD 0.68 a year ago. For the full year, operating loss was USD 45.117 million compared to operating Income of USD 52.817 million a year ago. Net loss was USD 43.842 million compared to net income of USD 56.823 million a year ago. Basic loss per share from continuing operations was USD 1.24 compared to basic earnings per share from continuing operations of USD 1.72 a year ago. Diluted loss per share from continuing operations was USD 1.24 compared to diluted earnings per share from continuing operations of USD 1.66 a year ago.